Gut microbiota–immune–barrier axis (GIB axis)

The gut microbiota–immune–barrier axis is a complex, multi-component system essential for maintaining systemic homeostasis and protecting the host from pathogens (Thursby & Juge, 2017). It consists of the intestinal microbiota, the physical epithelial barrier—including the mucus layer and tight junctions—and the underlying mucosal immune system (Vancamelbeke & Vermeire, 2017). This network functions by coordinating signals between commensal microorganisms and host immune cells to promote immune tolerance while preventing the translocation of harmful substances into the bloodstream (Belkaid & Hand, 2014). Dysregulation of this network, often termed dysbiosis or "leaky gut," is a hallmark of numerous conditions, including inflammatory bowel disease (IBD), metabolic disorders, and autoimmune diseases (Takiishi et al., 2017). Therapeutic strategies targeting this axis often involve modulating the microbiome via probiotics or fecal transplants, or reinforcing the barrier and immune response through targeted biologics (Gueimonde & Collado, 2012). Understanding this systems-level interaction is crucial for developing holistic treatments that address the root causes of chronic inflammation and metabolic dysfunction.

Other names

Gut-immune-microbiome axisIntestinal barrier-immune-microbiota networkMicrobiota-gut-immune axisGut-immune-barrier network

Drugs targeting this network act by neutralizing pro-inflammatory cytokines, blocking leukocyte trafficking to the gut mucosa, or restoring microbial diversity to strengthen the intestinal barrier and promote immune tolerance (Vancamelbeke & Vermeire, 2017).